Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

GROWTH HORMONE SUPPORTInvestigationalPopular

CJC-1295 (No DAC)

GHRH Analog · 10mg

Vial size

Status

Investigational

Route

SubQ

Half-life

~30 minutes plasma

Class

GHRH analog

MechanismGHRH Receptor Agonism

Cohort92 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$90 USD/vial

À-la-carte: $100 USD/vial · Save 10%

Vials per allocation

Member total (1×)$90

À-la-carte total$100

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Modified GHRH analog with optimized pharmacokinetics. Paired with ghrelin mimetics for synergistic GH pulse amplification.

GHRH Analog · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

CJC-1295 (No DAC) · Growth hormone support

◆ Certificate of Analysis · CJC-1295 (No DAC)

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Batch 001 · lot VL-CJC-2026-07A

Every 100 units are drawn from one lot and tested once. The certificate below is the one that applies to this batch - when it closes, the next opens with a new lot and a new certificate.

DEMO

Lot · VL-CJC-2026-05A

99.58%

Labeled

10 mg

Actual (HPLC)

10.24 mg

Method

HPLC + MS

Tested

May 09, 2026

Endotoxin

not tested for this lot

Heavy metals

not tested for this lot

◉

Clinical Overview

CJC-1295 (No DAC)

CJC-1295 (without DAC) is a tetrasubstituted GHRH analog. The "without DAC" designation indicates no Drug Affinity Complex, resulting in a shorter half-life that better mimics the natural pulsatile GH release pattern.

The version "with DAC" has a much longer half-life and is generally avoided in modern practice.

✦

GHRH Agonism

Stabilized GHRH analog amplifying GH pulses.

❖

Synergistic Pairing

Typically paired with a GHRP (e.g. Ipamorelin) for synergy.

◈

GH-Axis Support

Supports endogenous growth-hormone secretion.

◈

Mechanism

How It Works

GHRH receptor agonism with enhanced stability vs. native GHRH due to amino acid modifications. Typically paired with a GHRP (Ipamorelin or GHRP-2) for synergistic GH pulse amplification.

✚

Patient Bloodwork Guide

Bloodwork for Growth-Hormone Protocols

GHRH / GHRP secretagogues - Tesamorelin, CJC-1295, Ipamorelin, V-G1

These protocols gently restore your body’s own pulsing release of growth hormone rather than replacing it. Because growth hormone also affects blood sugar, monitoring confirms two things: that it is working, and that it is doing so safely.

Incremental approach. Vivre starts below the standard dose and advances only on tolerance. This monitoring is the safety scaffold for that conservative approach.

Is it working? (Efficacy)

IGF-1The main signal of your overall growth-hormone output across the day.

IGFBP-3The protein that carries IGF-1 - measured alongside it for a clearer picture of how much is active.

Blood sugar & metabolism (watch closely)

Fasting insulinThe earliest warning sign of insulin resistance - it moves before blood sugar does.

HbA1cYour average blood sugar over ~3 months. Especially relevant with Tesamorelin.

Fasting glucoseA routine blood-sugar check.

Keeping side effects in check

ProlactinIpamorelin (the one Vivre uses) is highly selective and rarely affects this; checked as good practice.

Cortisol (AM)A stress-hormone check included for completeness.

Overall safety

hs-CRPA sensitive inflammation marker - confirms recovery, not strain.

CBC & CMPStandard blood count, liver, and kidney panels.

When the tests happen

Baseline (before you start)Full panel - your natural starting point.

Mid-cycle (week 6–8)IGF-1, fasting insulin, prolactin/cortisol - confirm it works, catch sugar drift early.

Post-cycle (4 weeks off)IGF-1 and fasting insulin - confirm natural production recovers.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	GHRH analogue (no DAC variant)
Mechanism	GHRH-receptor agonism; stimulates endogenous GH pulsatility
Terminal half-life	No-DAC variant short-acting (~30 min order); DAC variant substantially longer
Metabolism	Peptidase degradation
Evidence base	Moderate; limited large controlled human trials
Regulatory status	Not an approved therapy; physician-supervised use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

PK differs markedly between DAC/no-DAC forms. Educational only; not a dosing instruction.

Clinical Literature

Peer-Reviewed References

Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295, a Long-Acting Analog of GHRH, in Healthy Adults

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · 2006 · Journal of Clinical Endocrinology & Metabolism 2006;91(3):799–805

▾

Findings

Two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21–61 (DOI 10.1210/jc.2005-1536). A single subcutaneous injection produced dose-dependent increases in mean plasma GH (2–10× for ≥6 days) and IGF-I (1.5–3× for 9–11 days); estimated half-life 5.8–8.1 days. After multiple doses, mean IGF-I stayed above baseline up to 28 days, with evidence of cumulative effect. No serious adverse reactions; well tolerated at 30–60 μg/kg. CRITICAL FRAMING: the studied agent was the DAC-modified long-acting variant, which produces SUSTAINED (continuous) GH/IGF-I elevation. Vivre uses the No-DAC (Mod GRF 1-29) form, which has a ~30-minute half-life and produces PULSATILE GH release that better mimics physiology. This study supports the GH-axis mechanism but does not endorse continuous-elevation (DAC) dosing for longevity use.

View on publisher ↗

CJC-1295 pharmacology is reasonably well-characterised across both DAC and No-DAC variants; the Teichman 2006 human data is for the DAC form. Vivre uses only the No-DAC variant - for its pulsatile (rather than sustained) GH-release profile. The distinction matters clinically: the DAC form binds albumin (~7–8 day half-life) and drives a continuous "GH bleed" - 24/7 GH/IGF-I elevation with no rest window - which raises the theoretical concerns around insulin resistance and chronic IGF-1 exposure (see the GH/IGF-1 safety reference). Many longevity physicians avoid the DAC form for exactly this reason. The No-DAC form's brief (~30 min) pulses return to baseline between doses, more closely mimicking youthful physiologic secretion. CJC-1295 is on the WADA Prohibited List as a GH secretagogue.

◇

Clinical Applications

Indications

GH optimization protocols
Body composition support
Recovery and sleep support
Component of GH-secretagogue stacks

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~30 minutes plasma (CJC-1295 without DAC; multiple published sources). Produces a clean discrete GH pulse via GHRH-receptor activation. The DAC-modified version, NOT offered at Vivre, has a much longer half-life (~6-8 days) but is associated with sustained rather than pulsatile GH elevation.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Limited human clinical trials. Widespread use in compounding pharmacy practice.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

◎

Commonly Paired

Compounds Often Prescribed With CJC-1295 (No DAC)

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

GHRP

Ipamorelin

Ghrelin Mimetic · 10mg

◆ GH-axis stack

CJC-1295 (No DAC) paired with Ipamorelin amplifies pulsatile GH release through complementary, non-competing pathways. This pairing IS Vivre's V-G1 protocol - pre-blended into a single vial (Jodomi JD-C104).

View Ipamorelin detail →

Growth Hormone Secretagogue

Sermorelin

GHRH Analog · 10mg

◆ alternative GHRH

Physician-selected alternative - sermorelin has a shorter half-life than CJC-1295 No-DAC and may be chosen for specific pulsatility profiles.

View Sermorelin detail →

READY TO PROCEED

Start with the Biological Audit

CJC-1295 (No DAC) is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$90 USD/vial

CJC-1295 (No DAC) · Member rate